State-of-the-art therapies for Rett syndrome.
Nicolas Panayotis, Yann Ehinger, Marie Solenne Felix and 1 others
PMID 36056801WHAT IT FOUND
Rett syndrome has no cure.
This review says current treatments only relieve symptoms, while gene replacement, gene editing and X-chromosome reactivation are preclinical strategies that need more work.
Key findings
01Rett syndrome is currently incurable, and available treatments aim to alleviate symptoms and improve quality of life.
02The review states its aim is to discuss strategies that allow each cell to express functional MeCP2 and potentially cure the pathology, rather than pharmacological approaches.
03The review discusses gene replacement, gene editing and X-chromosome reactivation, and states that MeCP2 dosage control and brain delivery remain problems.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
It is a review, not an original clinical trial, so it does not report new patient outcomes. It states that pharmacological approaches were not addressed. The strategies it discusses are described as preclinical, and further refinement is needed. It does not evaluate therapist-delivered rehabilitation or speech therapy.
Declared interests
Funding was from INSERM, Aix Marseille University, grants from AFM-Téléthon, Promex Stiftung Für Die Forschung, Rettsyndrome.org and Association Française du Syndrome de Rett. The supplied text lists funders but does not provide an author competing-interests declaration.
The easy way to misread this
Do not read the gene therapy, gene editing or X-chromosome reactivation strategies as available treatments. The review says Rett syndrome is currently incurable and these approaches are preclinical or still need refinement.